BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Eyupoglu ND, Caliskan Guzelce E, Acikgoz A, Uyanik E, Bjørndal B, Berge RK, Svardal A, Yildiz BO. Circulating gut microbiota metabolite trimethylamine N-oxide and oral contraceptive use in polycystic ovary syndrome. Clin Endocrinol (Oxf) 2019;91:810-5. [PMID: 31556132 DOI: 10.1111/cen.14101] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Mohd Shukri MF, Norhayati MN, Badrin S, Abdul Kadir A. Effects of L-carnitine supplementation for women with polycystic ovary syndrome: a systematic review and meta-analysis. PeerJ 2022;10:e13992. [DOI: 10.7717/peerj.13992] [Reference Citation Analysis]
2 Tayachew B, Vanden Brink H, Garcia-reyes Y, Rahat H, D'alessandro A, Frank DN, Robertson CE, Silveira L, Kelsey M, Pyle L, Cree-green M. Combined Oral Contraceptive Treatment Does Not Alter the Gut Microbiome but Affects Amino Acid Metabolism in Sera of Obese Girls With Polycystic Ovary Syndrome. Front Physiol 2022;13:887077. [DOI: 10.3389/fphys.2022.887077] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Batra M, Bhatnager R, Kumar A, Suneja P, Dang AS. Interplay between PCOS and microbiome: The road less travelled. Am J Reprod Immunol 2022;:e13580. [PMID: 35598286 DOI: 10.1111/aji.13580] [Reference Citation Analysis]
4 Chen W, Pang Y. Metabolic Syndrome and PCOS: Pathogenesis and the Role of Metabolites. Metabolites 2021;11:869. [PMID: 34940628 DOI: 10.3390/metabo11120869] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
5 Annunziata G, Ciampaglia R, Capò X, Guerra F, Sureda A, Tenore GC, Novellino E. Polycystic ovary syndrome and cardiovascular risk. Could trimethylamine N-oxide (TMAO) be a major player? A potential upgrade forward in the DOGMA theory. Biomed Pharmacother 2021;143:112171. [PMID: 34536755 DOI: 10.1016/j.biopha.2021.112171] [Reference Citation Analysis]
6 Duan L, An X, Zhang Y, Jin, Zhao S, Zhou R, Duan Y, Zhang Y, Liu X, Lian F. Gut microbiota as the critical correlation of polycystic ovary syndrome and type 2 diabetes mellitus. Biomed Pharmacother 2021;142:112094. [PMID: 34449321 DOI: 10.1016/j.biopha.2021.112094] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
7 Wei J, Qing Y, Zhou H, Liu J, Qi C, Gao J. 16S rRNA gene amplicon sequencing of gut microbiota in gestational diabetes mellitus and their correlation with disease risk factors. J Endocrinol Invest 2021. [PMID: 34302684 DOI: 10.1007/s40618-021-01595-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
8 He Y, Jin X, Wang H, Dai H, Lu X, Zhao J, Zhang H, Chen W, Wang G. The emerging role of the gut microbiome in polycystic ovary syndrome. F&S Reviews 2021;2:214-26. [DOI: 10.1016/j.xfnr.2021.03.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
9 Eyupoglu ND, Ergunay K, Acikgoz A, Akyon Y, Yilmaz E, Yildiz BO. Gut Microbiota and Oral Contraceptive Use in Overweight and Obese Patients with Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2020;105:dgaa600. [PMID: 32860695 DOI: 10.1210/clinem/dgaa600] [Cited by in Crossref: 7] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
10 Rizk MG, Thackray VG. Intersection of Polycystic Ovary Syndrome and the Gut Microbiome. J Endocr Soc 2021;5:bvaa177. [PMID: 33381671 DOI: 10.1210/jendso/bvaa177] [Cited by in Crossref: 3] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
11 Arias N, Arboleya S, Allison J, Kaliszewska A, Higarza SG, Gueimonde M, Arias JL. The Relationship between Choline Bioavailability from Diet, Intestinal Microbiota Composition, and Its Modulation of Human Diseases. Nutrients 2020;12:E2340. [PMID: 32764281 DOI: 10.3390/nu12082340] [Cited by in Crossref: 10] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]